Timothy Lazarek
Nurse Practitioner · San Diego, CANPI 1891881215
Payments from drug & device makers
Across 956 payments — averaging $38.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$8K
- Sanofi$5K
- Mallinckrodt Hospital Products Inc.$4K
- Boehringer Ingelheim$3K
- Amgen$3K
- AbbVie$2K
- plus $11K from 33 others
Across 1 payment — averaging $250.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$250
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 124 | $7,646 |
| Sanofi | 16 | $5,482 |
| Mallinckrodt Hospital Products Inc. | 61 | $4,476 |
| Boehringer Ingelheim | 38 | $3,349 |
| Amgen(2 entities) | 155 | $2,680 |
| AbbVie | 101 | $2,025 |
| Johnson & Johnson | 95 | $1,830 |
| ANI Pharmaceuticals, Inc. | 62 | $1,508 |
| Novartis | 66 | $1,155 |
| Fresenius Kabi USA, LLC | 1 | $1,125 |
| AstraZeneca(2 entities) | 40 | $952 |
| Pfizer | 43 | $897 |
| Aurinia Pharma U.S., Inc. | 21 | $786 |
| GSK | 35 | $770 |
| Lilly USA, LLC | 23 | $622 |
| Radius Health, Inc. | 7 | $192 |
| E.r. Squibb & Sons, L.L.C. | 7 | $177 |
| Actelion Pharmaceuticals US, Inc. | 15 | $169 |
| Kyowa Kirin, Inc. | 5 | $111 |
| Genentech USA, Inc. | 5 | $95 |
| Pacira Therapeutics, Inc. | 5 | $86 |
| Vision Quest Industries Inc. | 2 | $69 |
| Echosens North America, Inc. | 2 | $66 |
| Kiniksa Pharmaceuticals, Ltd. | 4 | $65 |
| Janssen Scientific Affairs, LLC | 1 | $63 |
| Octapharma USA, Inc. | 3 | $60 |
| Alnylam Pharmaceuticals Inc. | 2 | $49 |
| Ultragenyx Pharmaceutical Inc. | 2 | $46 |
| CSL Behring | 3 | $43 |
| Scilex Pharmaceuticals Inc. | 2 | $41 |
| Azurity Pharmaceuticals, Inc. | 2 | $34 |
| Merck | 1 | $30 |
| Hospira, Inc. | 1 | $26 |
| Biocryst US Sales Co., LLC | 1 | $24 |
| Sobi, Inc | 1 | $19 |
| Boston Scientific | 1 | $17 |
| Eisai Inc. | 1 | $16 |
| Bayer | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$36,829 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nurse practitioner in San Diego
- Angelina CollinsSan Diego$356K
- Madison ShreeveSan Diego$310K
- Arlene OrtegaSan Diego$135K
- Stacey RossSan Diego$43K
- Melanie McGillowaySan Diego$33K
- Jeremy FlowersSan Diego$26K
- Rhonda HewittStanford$917K
- Linda TrinhIrvine$899K
- Denise SinagaNorthridge$728K
- Debbie TaySanta Monica$642K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.